PPT Slide

Topical: Solaraze (Bioglan/Quintiles)

• HA technology: diclofenac gel for the treatment of actinic keratosis (AK):
  • Pre-cancerous skin condition

• FDA & EMEA approved

• Superior competitive profile and user friendly

• Under-treated: potential to expand market from dermatologist to GP

• U.S. market estimate: $250M
  • Affects 25% of adult population

Previous slide

Next slide

Back to first slide

View graphic version